Details of the Drug

General Information of Drug (ID: DM4EWNS)

Drug Name

Cinoxacin

Synonyms

Cinobac; Cinobactin; Cinoxacine; Cinoxacino; Cinoxacinum; Cinx; Clinoxacin; Uronorm; Azolinic Acid; C 8645; Lilly 64716; TNP00246; Cinobac (TN); Cinoxacine [INN-French]; Cinoxacino [INN-Spanish]; Cinoxacinum [INN-Latin]; Cinoxacin (JAN/USP/INN); Cinoxacin [USAN:BAN:INN:JAN]; 1-Ethyl-1,4-dihydro-4-oxo(1,3)dioxolo(4,5-g)cinnoline-3-carboxylic acid; 1-Ethyl-1,4-dihydro-4-oxo[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid; 1-Ethyl-4-oxo-1,4-dihydro[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid; 1-Ethyl-6,7-methylenedioxy-4(1H)-oxocinnoline-3-carboxylic acid; 1-ethyl-4-oxo-[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid

Indication

Disease Entry	ICD 11	Status	REF
Urinary tract infection	GC08	Approved	[1], [2]

Therapeutic Class

Antiinfective Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

262.22

Topological Polar Surface Area (xlogp)

2.1

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 4: low solubility and low permeability [3]
Bioavailability: 72.5% of drug becomes completely available to its intended biological destination(s) [4]
Elimination: 60% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 1.5 hours [5]
Metabolism: The drug is metabolized via the hepatic [6]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 63.68603 micromolar/kg/day [7]

Chemical Identifiers

Formula: C12H10N2O5
IUPAC Name: 1-ethyl-4-oxo-[1,3]dioxolo[4,5-g]cinnoline-3-carboxylic acid
Canonical SMILES: CCN1C2=CC3=C(C=C2C(=O)C(=N1)C(=O)O)OCO3
InChI: InChI=1S/C12H10N2O5/c1-2-14-7-4-9-8(18-5-19-9)3-6(7)11(15)10(13-14)12(16)17/h3-4H,2,5H2,1H3,(H,16,17)
InChIKey: VDUWPHTZYNWKRN-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 2762
ChEBI ID: CHEBI:3716
CAS Number: 28657-80-9
DrugBank ID: DB00827
TTD ID: D07UXP
ACDINA ID: D00947

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
DNA topoisomerase II (TOP2)	TT0IHXV	TOP2A_HUMAN; TOP2B_HUMAN	Inhibitor	[8]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Cinoxacin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Idarubicin	DMM0XGL	Minor	Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Idarubicin.	Acute myeloid leukaemia [2A60]	[15]
Aminophylline	DML2NIB	Moderate	Decreased metabolism of Cinoxacin caused by Aminophylline mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[16]
Temozolomide	DMKECZD	Minor	Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Temozolomide.	Brain cancer [2A00]	[15]
Lomustine	DMMWSUL	Minor	Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Lomustine.	Brain cancer [2A00]	[15]
Thiotepa	DMIZKOP	Minor	Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Thiotepa.	Breast cancer [2C60-2C6Y]	[15]
Ketoprofen	DMRKXPT	Moderate	Additive CNS depression effects by the combination of Cinoxacin and Ketoprofen.	Chronic pain [MG30]	[17]
Capecitabine	DMTS85L	Minor	Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Capecitabine.	Colorectal cancer [2B91]	[15]
Mestranol	DMG3F94	Moderate	Decreased absorption of Cinoxacin due to formation of complexes caused by Mestranol.	Contraceptive management [QA21]	[18]
Mycophenolic acid	DMU65NK	Moderate	Altered absorption of Cinoxacin due to GI flora changes caused by Mycophenolic acid.	Crohn disease [DD70]	[19]
Procarbazine	DMIK367	Minor	Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Procarbazine.	Hodgkin lymphoma [2B30]	[15]
Didanosine	DMI2QPE	Moderate	Decreased absorption of Cinoxacin due to formation of complexes caused by Didanosine.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Bempedoic acid	DM1CI9R	Major	Increased risk of tendinitis/tendon rupture by the combination of Cinoxacin and Bempedoic acid.	Hyper-lipoproteinaemia [5C80]	[21]
Meclofenamic acid	DM05FXR	Moderate	Additive CNS stimulant effects by the combination of Cinoxacin and Meclofenamic acid.	Inflammatory spondyloarthritis [FA92]	[22]
Iron	DMAP8MV	Moderate	Decreased absorption of Cinoxacin due to formation of complexes caused by Iron.	Iron deficiency anaemia [3A00]	[23]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Cinoxacin and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[24]
Lurbinectedin	DMEFRTZ	Minor	Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Lurbinectedin.	Lung cancer [2C25]	[15]
Fludarabine	DMVRLT7	Minor	Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Fludarabine.	Malignant haematopoietic neoplasm [2B33]	[15]
Mercaptopurine	DMTM2IK	Minor	Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Mercaptopurine.	Mature B-cell lymphoma [2A85]	[15]
Cytarabine	DMZD5QR	Minor	Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Cytarabine.	Mature B-cell lymphoma [2A85]	[15]
Mechlorethamine	DM0CVXA	Minor	Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Mechlorethamine.	Mature T-cell lymphoma [2A90]	[15]
Dacarbazine	DMNPZL4	Minor	Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Dacarbazine.	Melanoma [2C30]	[15]
Ethinyl estradiol	DMODJ40	Moderate	Decreased absorption of Cinoxacin due to formation of complexes caused by Ethinyl estradiol.	Menopausal disorder [GA30]	[18]
Lanthanum carbonate	DMMJQSH	Moderate	Decreased absorption of Cinoxacin due to formation of complexes caused by Lanthanum carbonate.	Mineral absorption/transport disorder [5C64]	[25]
Melphalan	DMOLNHF	Minor	Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Melphalan.	Multiple myeloma [2A83]	[15]
Deflazacort	DMV0RNS	Major	Increased risk of tendinitis/tendon rupture by the combination of Cinoxacin and Deflazacort.	Muscular dystrophy [8C70]	[26]
Hydroxyurea	DMOQVU9	Minor	Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Hydroxyurea.	Myeloproliferative neoplasm [2A20]	[15]
Busulfan	DMXYJ9C	Minor	Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Busulfan.	Myeloproliferative neoplasm [2A20]	[15]
Bupropion	DM5PCS7	Major	Increased risk of lowers seizure threshold by the combination of Cinoxacin and Bupropion.	Nicotine use disorder [6C4A]	[27]
Carboplatin	DMG281S	Minor	Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Carboplatin.	Ovarian cancer [2C73]	[15]
Topotecan	DMP6G8T	Minor	Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Topotecan.	Ovarian cancer [2C73]	[15]
Aspirin	DM672AH	Moderate	Additive CNS stimulant effects by the combination of Cinoxacin and Aspirin.	Pain [MG30-MG3Z]	[22]
Diflunisal	DM7EN8I	Moderate	Additive CNS depression effects by the combination of Cinoxacin and Diflunisal.	Pain [MG30-MG3Z]	[17]
Ibuprofen	DM8VCBE	Moderate	Additive CNS depression effects by the combination of Cinoxacin and Ibuprofen.	Pain [MG30-MG3Z]	[17]
Choline salicylate	DM8P137	Moderate	Additive CNS stimulant effects by the combination of Cinoxacin and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[28]
Salsalate	DM13P4C	Moderate	Additive CNS stimulant effects by the combination of Cinoxacin and Salsalate.	Rheumatoid arthritis [FA20]	[17]
Oxaprozin	DM9UB0P	Moderate	Additive CNS stimulant effects by the combination of Cinoxacin and Oxaprozin.	Rheumatoid arthritis [FA20]	[17]
Dexamethasone	DMMWZET	Major	Increased risk of tendinitis/tendon rupture by the combination of Cinoxacin and Dexamethasone.	Rheumatoid arthritis [FA20]	[26]
Dactinomycin	DM2YGNW	Minor	Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Dactinomycin.	Solid tumour/cancer [2A00-2F9Z]	[15]
Methylprednisolone	DM4BDON	Major	Increased risk of tendinitis/tendon rupture by the combination of Cinoxacin and Methylprednisolone.	Solid tumour/cancer [2A00-2F9Z]	[26]
Ifosfamide	DMCT3I8	Minor	Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Ifosfamide.	Solid tumour/cancer [2A00-2F9Z]	[15]
Docetaxel	DMDI269	Minor	Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Docetaxel.	Solid tumour/cancer [2A00-2F9Z]	[15]
Mitoxantrone	DMM39BF	Minor	Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Mitoxantrone.	Solid tumour/cancer [2A00-2F9Z]	[15]
Prednisolone	DMQ8FR2	Major	Increased risk of tendinitis/tendon rupture by the combination of Cinoxacin and Prednisolone.	Solid tumour/cancer [2A00-2F9Z]	[26]
Taxol	DMUOT9V	Minor	Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Taxol.	Solid tumour/cancer [2A00-2F9Z]	[15]
Doxorubicin	DMVP5YE	Minor	Decreased absorption of Cinoxacin due to intestinal mucosa variation caused by Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[15]
-----------


⏷ Show the Full List of 45 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Erythrosine sodium anhydrous	E00324	27872	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Food blue 1 aluminum lake	E00512	11979396	Colorant
Gelatin	E00630	Not Available	Other agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Cyclomethicone	E00203	10913	Emollient; Humectant; Viscosity-controlling agent
Pregelatinized starch	E00674	Not Available	Binding agent; Diluent; Disintegrant
--------------------


⏷ Show the Full List of 10 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Cinoxacin 250mg capsule	250mg	Capsule	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 018067.
3	BDDCS applied to over 900 drugs
4	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J Pharmacol Exp Ther. 1999 Aug;290(2):672-7.
9	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
10	Etoposide, topoisomerase II and cancer.Curr Med Chem Anticancer Agents.2005 Jul;5(4):363-72.
11	Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6.
12	Inhibition of human topoisomerase IIalpha by fluoroquinolones and ultraviolet A irradiation. Toxicol Sci. 2002 Sep;69(1):16-22.
13	Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Des. 2000 Dec;6(18):1811-39.
14	Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121.
15	Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
16	Ball P "Ciprofloxacin: an overview of adverse experiences." J Antimicrob Chemother 18 (1986): 187-93. [PMID: 3542945]
17	Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
18	Friedman CI, Huneke AL, Kim MH, Powell J "The effect of ampicillin on oral contraceptive effectiveness." Obstet Gynecol 55 (1980): 33-7. [PMID: 7188714]
19	Product Information. CellCept (mycophenolate mofetil). Roche Laboratories, Nutley, NJ.
20	Deppermann KM, Lode H "Fluoroquinolones: interaction profile during enteral absorption." Drugs 45 Suppl 3 (1993): 65-72. [PMID: 7689454]
21	Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
22	Davey PG "Overview of drug interactions with the quinolones." J Antimicrob Chemother 22(suppl c) (1988): 97-107. [PMID: 3053579]
23	Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5. [PMID: 2334155]
24	Product Information. Suprep Bowel Prep Kit (magnesium/potassium/sodium sulfates). Braintree Laboratories, Braintree, MA.
25	Canadian Pharmacists Association.
26	FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008].".
27	Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
28	Product Information. Avelox (moxifloxacin) Bayer, West Haven, CT.